Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Feigin

Showing results (41-50 of 62) with videos related to

Pageof 7
Sort By:
International Neurourology Journal|October 15, 2019
Urodynamic Mechanisms Underlying Overactive Bladder Symptoms in Patients With Parkinson DiseaseGregory Vurture, Benoit Peyronnet, Jose-Alberto Palma, et al.
JCI Insight|October 20, 2017
Increased putamen hypercapnic vasoreactivity in levodopa-induced dyskinesiaVincent A Jourdain, Katharina A Schindlbeck, Chris C Tang, et al.
Brain : a Journal of Neurology|September 12, 2014
A disease-specific metabolic brain network associated with corticobasal degenerationMartin Niethammer, Chris C Tang, Andrew Feigin, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Drug DevelopmentElizabeth E Evans, Terrence L Fisher, Vikas Mishra, et al.
Frontiers in Human Neuroscience|May 30, 2023
Art therapy as a comprehensive complementary treatment for Parkinson's diseaseTom Ettinger, Marygrace Berberian, Ikuko Acosta, et al.
Journal of the Neurological Sciences|January 17, 2020
Rapid picture naming in Parkinson's disease using the Mobile Universal Lexicon Evaluation System (MULES)Jenna Conway, Marissa Ilardi, Caroline Gonzalez, et al.
Parkinsonism & Related Disorders|July 25, 2018
Mirabegron in patients with Parkinson disease and overactive bladder symptoms: A retrospective cohortBenoit Peyronnet, Gregory Vurture, Jose-Alberto Palma, et al.
Nature Medicine|August 8, 2022
Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trialAndrew Feigin, Elizabeth E Evans, Terrence L Fisher, et al.
The Lancet. Neurology|January 27, 2024
Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 studyRalf Reilmann, Karen E Anderson, Andrew Feigin, et al.
Archives of Neurology|February 10, 2010
A randomized, placebo-controlled trial of latrepirdine in Huntington diseaseKarl Kieburtz, Michael P McDermott, Tiffini S Voss, et al.
Pageof 7

Showing results (41-50 of 62) with videos related to

Sort By:
Pageof 7
International Neurourology Journal|October 15, 2019
Urodynamic Mechanisms Underlying Overactive Bladder Symptoms in Patients With Parkinson DiseaseGregory Vurture, Benoit Peyronnet, Jose-Alberto Palma, et al.
JCI Insight|October 20, 2017
Increased putamen hypercapnic vasoreactivity in levodopa-induced dyskinesiaVincent A Jourdain, Katharina A Schindlbeck, Chris C Tang, et al.
Brain : a Journal of Neurology|September 12, 2014
A disease-specific metabolic brain network associated with corticobasal degenerationMartin Niethammer, Chris C Tang, Andrew Feigin, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 26, 2025
Drug DevelopmentElizabeth E Evans, Terrence L Fisher, Vikas Mishra, et al.
Frontiers in Human Neuroscience|May 30, 2023
Art therapy as a comprehensive complementary treatment for Parkinson's diseaseTom Ettinger, Marygrace Berberian, Ikuko Acosta, et al.
Journal of the Neurological Sciences|January 17, 2020
Rapid picture naming in Parkinson's disease using the Mobile Universal Lexicon Evaluation System (MULES)Jenna Conway, Marissa Ilardi, Caroline Gonzalez, et al.
Parkinsonism & Related Disorders|July 25, 2018
Mirabegron in patients with Parkinson disease and overactive bladder symptoms: A retrospective cohortBenoit Peyronnet, Gregory Vurture, Jose-Alberto Palma, et al.
Nature Medicine|August 8, 2022
Pepinemab antibody blockade of SEMA4D in early Huntington's disease: a randomized, placebo-controlled, phase 2 trialAndrew Feigin, Elizabeth E Evans, Terrence L Fisher, et al.
The Lancet. Neurology|January 27, 2024
Safety and efficacy of laquinimod for Huntington's disease (LEGATO-HD): a multicentre, randomised, double-blind, placebo-controlled, phase 2 studyRalf Reilmann, Karen E Anderson, Andrew Feigin, et al.
Archives of Neurology|February 10, 2010
A randomized, placebo-controlled trial of latrepirdine in Huntington diseaseKarl Kieburtz, Michael P McDermott, Tiffini S Voss, et al.
Pageof 7